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Conflic
search coObjectives: Patients with severe chronic obstructive pulmonary disease (COPD) have a high risk of lung cancer
and of postsurgical complications. We studied outcomes after stereotactic body radiotherapy (SBRT) in patients
with severe COPD, as defined by Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, and
performed a systematic review of the literature on outcomes after SBRT or surgery in these patients.
Methods: A single-institution cohort of 176 patients with COPD GOLD III-IV and Stage I non–small-cell lung
cancer (NSCLC) treatedwith SBRTwas evaluated. A systematic review identified studies reporting outcomes after
SBRTor surgery for Stage I NSCLC in patients with GOLD III-IVor a predicted postoperative forced expiratory
volume in 1 second (FEV1) of #40%.
Results: In the single-institution cohort, median follow-up was 21 months and median overall survival (OS) was 32
months. Actuarial 3-year local control was 89%, and 1- and 3-year OS were 79% and 47%, respectively. COPD
severity correlated with OS (p = 0.01). The systematic review identified four other studies (two surgical, two
SBRT, n = 196 patients). SBRT studies were published more recently and included older patients than surgical
studies. Mean 30-day mortality was 0% post-SBRT and 10% after surgery. Local or locoregional control was
high ($89%) after both treatments. Post-SBRT, actuarial OS was 79–95% at 1 year and 43–70% at 3 years. Post-
surgical actuarial OS was 45–86% at 1 year and 31–66% at 3 years.
Conclusions: SBRTand surgery differ in risk of 30-daymortality in patients with severe COPD. Despite the negative
selection of SBRTpatients, survival at 1 and 3 years is comparable between the two treatments.
 2012Elsevier Inc. Open access under the Elsevier OA license.Non–small-cell lung cancer, Chronic obstructive pulmonary disease, Surgery, Stereotactic body radiation therapy.INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is present in
50–70% of patients with lung cancer at the time of diagnosis
(1). COPD is an independent predictor of lung cancer, even
after controlling for smoking history (1–3). Lung cancer
risk increases as forced expiratory volume in 1 second
(FEV1) decreases, with the risk highest in patients with an
FEV1 of less than 40% of predicted (1–3). Patients with
severe COPD have a high annual mortality rate (4, 5), even
in the absence of malignancy. COPD itself is associated
with other comorbid conditions (including cardiovascular
disease), which can in turn further reduce suitability foreatment (6).
t requests to: David Palma, M.D., Department of Radia-
logy, London Regional Cancer Program, 790 Commis-
d. E, London, Ontario, Canada, N6A4L6, Phone: (519)
x56859; Fax: (519) 685-8627; E-mail: david.palma@
ts of interest: The VUUniversity Medical Center has a re-
llaboration with Varian Medical Systems.
1149Surgery has historically been the primary treatment option
for patients with Stage I non–small-cell lung cancer
(NSCLC). Although Stage I NSCLC is technically curable,
the presence of severe COPD increases the risk of postoper-
ative complications and reduces the extent of lung that can
be safely resected (7, 8). Because nonsurgical treatment
options such as conventional radiotherapy have historically
achieved suboptimal outcomes (9), some have argued that
the risks associated with surgery in patients with severe
COPD were justified (10). Recent surgical guidelines have
even suggested lowering the predicted postoperative FEV1
(ppo-FEV1) high-risk threshold from <40% of predicted to
<30% (8).
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provided a safe and effective alternative treatment for Stage I
NSCLC in patients who are unfit for surgery or decline
resection (11, 12). The role of SBRT in low-risk patients
who are fit to undergo surgery is being investigated in the
Phase III setting (13). Given the higher complication rates
and long-term competing mortality risks associated with
severe COPD, we evaluated post-SBRToutcomes in a cohort
of Stage I NSCLC patients with severe COPD, as defined by
the Global Initiative for Chronic Obstructive Lung Disease
(GOLD) criteria (14). Because the benefits of expanding
surgical access to such a population are not readily evident,
we also conducted a systematic review of the published lit-
erature, to allow for a broader assessment of outcomes after
surgery or SBRT in these patients.
METHODS
The objectives of this study were as follows:
1. To determine local control and survival outcomes after curative-
intent treatment (surgery or SBRT) for Stage INSCLC in patients
with severe COPD or ventilatory impairment.
2. To determine treatment complication rates and 30-day mortality
in this patient population.VU University Medical Center series
All patients with severe COPD who were treated with SBRT for
Stage I NSCLC at the VU University Medical centre (VUmc)
between inception of the SBRT program in 2003 and March 2010
were included in this study. COPD severity was defined according
to the GOLD criteria (14): severe if FEV1/forced vital capacity
(FVC) <70% and FEV1 30–50% predicted (GOLD Class III)
band very severe if FEV1/FVC <70% and FEV1 <30% predicted
(GOLD Class IV).
All patients are discussed by a multidisciplinary oncology tumor
board before treatment and entered into a prospective database. The
risk-adapted fractionation schemes and treatment planning tech-
niques have been described in detail elsewhere (15–17). Most
patients (n = 157) were treated with fixed-gantry multiple beam
SBRT delivery; the remainder (n = 19) were treated with volumetric
modulated arc therapy (RapidArc, Varian Medical Systems Inc,
Palo Alto, CA), which was implemented in 2008. No patients
received adjuvant chemotherapy.
Treatment planning for static beam plans was performed with the
BrainLab software (Brainscan v. 5.2, BrainLab Inc., Feldkirchen,
Germany) using 8–12 noncoplanar static beams and 6-MV photons.
RapidArc plans consisted of at least one pair of 358 clockwise and
counterclockwise coplanar arcs using 6-MV photons.
Fractionation choice was dependent on tumor size and location
(13, 15–17). T1 tumors surrounded by lung parenchyma were
treated in three fractions. T2 tumors, or T1 tumors with broad
contact with the chest wall, were treated in five fractions.
Centrally located tumors and tumors adjacent to the brachial
plexus were treated in eight fractions. The nominal prescribed
doses depended on the dose calculation algorithm used. With the
pencil beam algorithm used in the BrainLab software, the three
fractionations were: 3  20 Gy, 5  12 Gy, or 8  7.5 Gy. With
the AAA algorithm used for the RapidArc patients, the
fractionations were 3  18 Gy, 5  11 Gy, or 8  7.5 Gy. SBRT
doses were prescribed at the 80% isodose line. Four-dimensionalcomputed tomography (CT) scans (GE Medical Systems, Wauke-
sha, WI) were used to delineate internal target volumes. A planning
target volumemargin of 3–5 mmwas added to account for potential
baseline tumor shifts and setup errors. Respiratory gating was not
routinely used.
Routine practice requires outpatient assessments at 3 to 6
monthly intervals post-SBRT, with a diagnostic scan performed
at each visit. Toxicity was assessed using the Common Terminol-
ogy Criteria for Adverse Events, version 3.0 (18). Posttreatment
pulmonary function was not measured routinely.
Systematic review
Study inclusion criteria.
1. Studies reporting on clinically and/or pathologically staged
Stage I NSCLC
2. All patients must have had either a pretreatment FEV1 #50%
(corresponding to GOLD Class III/IV), or ppo-FEV1 #40%.
Although the relationship between preoperative and postopera-
tive FEV1 varies by individual patient, these cutoffs appear to be
similar, based on studies reporting both values (19–21).
Percent predicted FEV1valueswere used because they are amore
accurate indicator of pulmonary function than absolute values and
they minimize confounding effects of height, sex, and age (22,
23). In cases in which means and standard deviations/standard
errors of FEV1 values were reported in place of ranges, the
cutoffs above had to lie at least two standard deviations above the
mean for the study to be included. In studies reporting a subgroup
of patients meeting the above criteria, only that subgroup was
included in this review.
Exclusion criteria.
 Studies published only as conference abstracts
 Less than 20 patients in the applicable subgroup
 Only absolute FEV1 values reported (not predicted values)
 Published before 1995 (because of changes in surgical, anaes-
thetic, and radiotherapy technology)
 Outcomes for Stage I patients not specified separately in the
article
 Outcomes reported after conventional radiotherapy only
Search strategy.
Combinations of terms were used to search theMEDLINE and EM-
BASE electronic databases from 1995 until March 2010, relating to
the following concepts:
 lung cancer (‘‘lung cancer’’, ‘‘lung neoplasms’’, etc.)
 stage one (‘‘early stage’’, ‘‘stage 1’’, ‘‘stage I’’, etc.)
 pulmonary function: (‘‘forced expiratory’’, ‘‘FEV1’’, ‘‘chronic
obstructive pulmonary disease’’, ‘‘pulmonary function’’, etc.),
Both text and exploded Medical Subject Heading (i.e., MeSH)
termswere used. The searchwas conducted by a librarian and a phy-
sician. Only English-language articles were included. Studies were
screened by abstract (MEDLINE n = 224; EMBASE n = 120), and
146 full articles were retrieved, usually because outcomes stratified
by pulmonary function or stage were not specified in the abstracts.
Thirty-one articles (including three other systematic reviews) were
selected for detailed review and their reference lists were hand-
searched.
Eight articles fulfilled all the inclusion criteria. They were
assessed by two independent data abstractors (D.P., G.B.R.), and
any disagreements between the two abstractors were resolved by
consensus. Three of these were from a single institution (Glenfield
Hospital, UK) and included overlapping patient groups (19–21);
Fig. 1. Outcomes for 176 patients with severe chronic obstructive
pulmonary disease (COPD) and Stage I non–small-cell lung cancer
treated with stereotactic radiotherapy between 2003 and 2010.
(A) Local control; (B) overall survival; (C) overall survival stratified
by COPD severity. FEV1 = forced expiratory volume in 1 second.
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considered to be the definitive update and is reported herein. Data
from the two earlier studies were used only if they provided
further specific information not included in the latest study. One
study (Cancer and Leukemia Group B 9335) that specifically
enrolled high-risk patients only reported the median FEV1; it was
excluded after obtaining more complete data on baseline lung func-
tion by contacting the Cancer and Leukemia Group B (24). One sur-
gical study from 1995 was excluded as it reported on a cohort of
patients Stage I patients with respiratory impairment who all under-
went pneumonectomy, which was not felt to be reflective of current
practice for treatment of Stage I NSCLC (25).
Ultimately, four other studies were included in the systematic
review (19, 26–28). For one SBRT study (27), some data were ab-
stracted from an earlier report on the same cohort of patients (29).
No studies of surgery with intraoperative brachytherapy or
surgery with additional lung volume reduction met the inclusion
criteria.
Statistical analysis
For VUmc data, Kaplan-Meier survival estimates were generated
and differences compared using the log–rank test. Median follow-
up was calculated using the reverse Kaplan-Meier method. For
abstraction of survival data for the systematic review, 30-day mor-
tality, median survival, and 1-, 3-, and 5-year survivals were
estimated from the graphs if not provided in the text. If a large dis-
crepancy was noted between a Kaplan-Meier curve and the associ-
ated text, the data from the graph was used. All statistical tests were
two-sided with p # 0.05 indicative of statistical significance, and
all statistical analyses were performed using the Statistical Package
of Social Sciences (SPSS version 15.0, Chicago, IL).
RESULTS
VUmc SBRT patients and outcomes
A total of 176 patients with COPD scored as GOLD III
(n = 133) or IV (n = 43) with Stage I NSCLC were treated
between 2003 and March 2010. The median age was 70
years (range, 47–86), and most patients were male (n = 97;
55%). The median Charlson comorbidity score was four
(range, 2–9), and 96% were considered medically inopera-
ble. The median FEV1 was 0.94 L (range, 0.36–1.99 L),
corresponding to 38% of predicted (range, 16–50% of pre-
dicted).
All patients underwent a pretreatment FDG-positron
emission tomography (PET) scan. Many patients did not
have pathological confirmation of malignancy (n = 119;
68%). Although a biopsy was sought wherever safely possi-
ble, the risk of transthoracic biopsy was often considered too
high by the treating physician, given the poor baseline lung
function of this population. For patients without pathologi-
cal confirmation of malignancy, the median probability of
malignancy, based on a validated calculation algorithm
that includes patient history, CT, and PET, was 96.4% (30).
Most patients had T1 disease (n = 111; 63%), and 16
patients had a second primary T1 tumor treated synchro-
nously. The median planning target volume was 26 mL.
Most patients received the three-fraction scheme (n = 78;
44%); 69 (39%) received five fractions; and 29 (17%)
received eight fractions.Early side effects, occurring within 6 weeks of treatment,
were common and mild, with most patients (55%) experi-
encing Grade 1 or 2 toxicity (most commonly fatigue n =
55, cough and/or dyspnea n = 24, chest wall pain n = 18,
Table 1. Characteristics of five studies reporting outcomes after curative intent surgery or stereotactic body radiotherapy for patients
with poor ventilatory function
First author Institution
Publication
year
Accrual
period n Treatment
Surgery
Magdeleinat (26) Hopital Hotel Dieu and Lannelongue
Surgical centre, Paris, France
2005 1983–2003 58 Segmentectomy or
wedge (n = 15)
Lobectomy or greater (n = 43)
Lau (19) Glenfield Hospital, Leicester, UK 2010 1997–2009 63 Open segmentectomy or
VATS procedure (n = 43)
Open lobectomy (n = 20)
SBRT
Henderson (27) Indiana University, USA 2008 2002–2004 33 60–66 Gy/3 fractions
Stephans (28) Cleveland Clinic, USA 2009 2004–2007 42 50 Gy/10 fractions to 60
Gy/3 fractions
Palma (current study) VU University Medical centre,
Netherlands
2010 2003–2010 176 60 Gy/38 fractions
Abbreviations: n = number of patients; RT = radiotherapy; SBRT = stereotactic body radiotherapy; VATS = video-assisted thoracoscopic
surgery.
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early Grade 3 radiation pneumonitis. Late side effects (oc-
curring >6 weeks after treatment) of Grade 3 or more were
uncommon: there were 2 patients with Grade 3 radiation
pneumonitis, 2 patients with rib fractures, and 1 patient
with hemoptysis requiring transfusion. All Grade 3 toxicities
ultimately resolved.
The median length of follow-up was 21 months. There
were 8 local relapses (crude rate 4.5%), 12 regional relapses,
34 distant relapses, and 62 deaths (with some patients hav-
ing more than one of these events). Three-year actuarial lo-
cal control was 89% (Fig. 1A). Overall survival was 79% at
1 year, 47% at 3 years, and 28% at 5 years (Fig. 1B). Esti-
mates beyond 3 years are less reliable due to low patient
numbers. Patients with GOLD IV COPD had worse survival
than those with GOLD III COPD, with a median survival of
17 months vs. 36 months, respectively (Fig. 1C, log–rank
p = 0.01).
Systematic review
The characteristics of the four studies identified in the sys-
tematic review, along with the current study, are shown inTable 2. Baseline patie
First author
Age
(Mean or Median)
Surgery
Magdeleinat (26) 62* Path
Lau (19) 69* Unco
SBRT
Henderson (27) 70.5* Clini
Stephans (28) 74* Clini
Palma (current study) 70 Clini
Abbreviations: FEV1 = baseline forced expiratory volume in 1 second
(as percent predicted); NR = not reported.
* Value not reported for subgroup of interest; the value listed appliesTable 1. Two studies reported on surgery (total n = 121
patients) and two on SBRT (total n = 75 patients). In all
four studies, Stage I patients with poor FEV1 represented
a subgroup of all patients included in the report.
Patient and tumor characteristics are shown in Table 2.
Patients in the SBRT studies were older than those in the sur-
gical studies (weighted mean 71 vs. 66 years old). The sur-
gical reports included patients with pathologically staged
disease, whereas SBRT studies reported on patients who
were clinically staged, and included PET scans in the staging
algorithm.
Complications and 30-day mortality. Complications and
30-day mortality are shown in Table 3. Reporting of compli-
cations for this specific subgroup of patients was limited.
The surgical studies had discordant rates of intensive care
unit admission (>90% vs <10% admitted), likely reflecting
different institutional policies. Median hospital stay ranged
from 8 to 12 days after surgery.
SBRT appeared to be well tolerated with minor toxicity.
The Henderson et al. SBRT study did not report complica-
tion rates specifically for the subgroup of patients with
severe COPD, but in the whole cohort of patients enrollednt characteristics
Stage
FEV1
(Mean or Median)
ological stage I 40% (range, 23–50%)*
mplicated pathological stage I ppo-FEV1: 33%
(range, 14–40%)*
FEV1: 41%
(range, 18–54%)*
cal stage I NR (range, 13–46%)
cal stage I NR (range, 15–50%)
cal stage I 38% (range, 16–50%)
(as percent predicted); ppo-FEV1 = predicted postoperative FEV1
to the whole study population.
Table 3. Thirty-day mortality and complications associated with treatment of stage I NSCLC in patients with poor ventilatory function
First author 30-day mortality Complications
Surgery
Magdeleinat (26) 8%* >90% admitted to ICU
>45% with complications (pneumonia,
air leak, and arrhythmia most common)
Lau (19) 25% after open lobectomy*
7% for open segmentectomy
or VATS procedure*
Median hospital stay 8–12 days
<10% admitted to ICU
SBRT
Henderson (27) 0%* >69% with Grade 1 or 2 toxicity of some kindy
Stephans (28) 0%* No Grade 3 or higher pneumonitis
Palma (current study) 0% 6 patients (3%) with Grade 3 toxicity
Abbreviations: ICU = intensive care unit; VATS = video-assisted thoracoscopic surgery.
* Denotes values measured from Kaplan-Meier curves.
y 8%Grade 3–4 toxicity with some late deaths related to treatment of central tumors in larger Phase II study, but these rates not specified for
subgroup with poor pulmonary function.
Treatment of stage I NSCLC with severe COPD d D. PALMA et al. 1153in the Phase II trial, 8% experienced Grade 3–4 toxicity, and
excessive late toxicity was noted in patients who received 60
Gy in three fractions to central tumors (29). It cannot be de-
termined from the reports if patients in this poor-ventilatory
subgroup experienced those toxicities.
There was no 30-day mortality after SBRT. After surgery,
the 30-daymortality ranged from7% to25%,with aweighted
mean of 10%.
Local control and survival. Locoregional control after sur-
gery was reported in two of the earlier surgical articles from
Glenfield Hospital (20, 21) that were considered subsets of
Lau et al., and ranged from 89% to 94%, although patients
did not undergo routine follow-upCT scans. All SBRT studies
reported local control rates of 89% or greater (27, 28).
Long-term outcomes are shown in Table 4 and Fig. 2. Me-
dian follow-up in the surgical studies ranged from 3.4 to 4.7
years, longer than the median follow-up available for SBRT
patients (1.5–2.2 years). Long-term survival is attainable after
SBRT and surgery. There was substantial overlap in survival
outcomes between the two treatmentmodalities at all time pe-
riods. Very few patients were available for follow-up beyond 3Table 4. Length of follow-up and survival outcomes after tre
with poor ventilat
First author
Follow-up (y)
(Mean or Median)
Surgery
Magdeleinat (26) 3.4y
Lau (19) 4.7y
Open segmentectomy or VATS:
Open lobectomy:
SBRT
Henderson (27) 2.2y
Stephans (28) 1.5y
Palma (current study) 1.7
Abbreviations: OS = overall survival; VATS = video-assisted thoracos
Empty cells denote values not reported and unavailable from Kaplan-
* Denotes values measured from Kaplan-Meier curves.
y Value is reported for whole study population (not just Stage I patienyears, rendering the longest estimates less reliable. The worst
survival outcomes reported after surgerywere in a subgroup of
patients who underwent open lobectomy (8%5-year survival).
DISCUSSION
This single-institutional study and systematic review of
observational studies suggests that SBRTachieves compara-
ble long-term survival outcomes to surgical resection for
patients with Stage I NSCLC in the setting of severe COPD
or ventilatory dysfunction. SBRT is associated with low risks
of operative mortality, rarely requires a hospital stay, and is
associated with a favorable toxicity profile. However, this
review indicates that published data reporting survival out-
comes in patients with severe COPD and Stage I NSCLC
are lacking. Comparisons of outcomes across studies can
be biased by differences in baseline populations, and defini-
tive conclusions cannot be made.
However, the long-term survival of patients in this review
is relatively poor, compared with the general population of
patients with Stage I NSCLC (31), likely because of a higher
risk of death from non–lung cancer causes. In the first USatment of Stage I non–small-cell lung cancer in patients
ory function
Median OS (y)
Percent surviving
1 y 3 y 5 y
4.2 84%* 63%* 44%
5.5* 86%* 66%* 50%*
0.8* 45%* 31%* 8%*
1.6 91%* 43%*
Not reached* 95%* 70%*
2.7 79% 47% 28%
copic surgery.
Meier curves.
ts with poor ventilatory function).
Fig. 2. Survival outcomes for patients with Stage I NSCLC with
severe ventilatory dysfunction after surgery or stereotactic radio-
therapy (SBRT). Values plotted are 1-year, 3-year and 5-year over-
all survival as extracted from Kaplan-Meier curves. Superscript
numbers refer to references. C = current study.
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patients with severe COPD had died within 5 years (4). In
the US National Emphysema Treatment Trial comparing
medical therapy with lung volume reduction for patients
with severe COPD (median FEV1 27% predicted), the
annual death rate was 11% (32). This high competing risk
of death from non–cancer causes can result in a lower rate
of lung cancer death: in the Lau study included in this
review, only 37% of deaths were cancer-related (19). As
a result, small differences in oncologic outcomes between
surgery and SBRT could take on lesser importance in deter-
mining survival.
The use of surgery or SBRTas primary treatment for Stage
I NSCLC has been the subject of increasing recent interest,
and the question is being examined in Phase III trials (13).
However, even after these are completed, the outcomes
may not necessarily apply to patients with severe COPD;
this will depend on the characteristics of patients enrolled.
Recently, Markov modeling was used to simulate a clinical
trial comparison of SBRT and surgery, with a small survival
advantage predicted for surgery over SBRT of 2–3% at 5
years. This effect was highly sensitive to the predicted oper-
ative mortality rate; after operative mortality increased
above 4%, SBRT appeared more favorable (33). In this sys-
tematic review, the SBRT patients are a negatively selected
group, in terms of age, lack of fitness for surgery, and report-
ing of outcomes for clinically staged (rather than patholog-
ically staged) disease. Yet despite this negative selection,
SBRToutcomes do not appear to be inferior than those after
surgery.
Surgery confers two theoretical advantages over SBRT:
because it is invasive, definitive pathological diagnosis and
more complete nodal staging are possible. These theoretical
benefits should be carefully considered. A lack of patholog-ical confirmation may be considered as a weakness of some
SBRT studies, where many patients do not have pathological
confirmation of diagnosis. Often poor lung function pre-
cludes safe biopsy, and in such cases malignancy risk can
estimated using clinical and imaging findings. This has
been validated in several studies and has been confirmed to
results in a low rate of benign disease at thoracotomy (30,
34–36). In a previous population-based study in North Hol-
land, radiotherapy patients treated without pathological
diagnosis had a markedly inferior survival (hazard ratio of
death of >2, compared with radiotherapy patients with
a pathological diagnosis), likely reflecting death from the
underlying comorbidities that initially precluded biopsy
(37). Although the more definitive nodal staging provided
by surgery could theoretically be beneficial (e.g., in remov-
ing occult disease or identifying patients for chemotherapy),
these benefits are likely to be negligible in patients with
severe COPD, considering the poor general condition and
high risk of intercurrent death of these patients, the relatively
low risk of occult nodal disease in Stage I patients (approx-
imately 15%) (38), and the small absolute benefit of adjuvant
chemotherapy in those who receive it (5% at 5 years) (39).
Furthermore, in patients with respiratory impairment, com-
pliance with systematic ipsilateral lymph node sampling
procedures is poor (24).
This study must be considered in the context of its limita-
tions. All studies reported herein were observational, and as
such are subject to the biases inherent in nonrandomized
studies. Not all information of interest was captured in the
VUMC SBRT database; specifically, extensive pretreatment
dose–volume histogram information would be useful in this
patient population with severe COPD. For this systematic
review, a prespecified cutoff of pulmonary function was
required to ensure that all included patients had pulmonary
dysfunction. However, FEV1 is only one surrogate for pul-
monary dysfunction, whereas treatment decisions should
be based on more comprehensive pulmonary testing and
physiological assessments (7). Not all patients with FEV1
<50% predicted will have COPD, and more comprehensive
scales assessing COPD severity are available (40). However,
for purposes of systematically reviewing the literature,
FEV1 is commonly reported and can distinguish between
the different GOLD levels of severity. This cutoff may also
limit the generalizability of the study. Despite use of strict
inclusion criteria in this review, the differences in patient se-
lection, staging investigations, follow-up, extent of surgery
(e.g., video-assisted thoracoscopic surgery vs. open surgery)
and radiotherapy doses hamper direct comparisons between
studies. Finally, data are not available on all outcomes of
importance, especially baseline comorbidities and posttreat-
ment quality of life.CONCLUSION
Limited published data are available to assess outcomes
after curative treatment of Stage I NSCLC in the setting of
severe COPD. SBRT is a safe and effective treatment option
Treatment of stage I NSCLC with severe COPD d D. PALMA et al. 1155for these patients, with outcomes that do not appear to be
inferior to surgery. SBRT is not associated with the consider-
able initial risks of operative mortality and prolonged hospi-
talization. Patients who do undergo surgery may benefit
from avoiding open lobectomy, instead using less invasiveapproaches such as video-assisted thoracoscopic surgery or
open segmentectomy. All patients with Stage I NSCLC
and severe COPD should be evaluated in a multidisciplinary
setting and afforded an informed decision of the risks and
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